Archive · 17 Nov 2025
Marksans Pharma's UK Subsidiary Approved for Pain Relief Tablets
A company called Marksans Pharma has a branch in the UK.
The UK's health agency has given this branch permission to sell a new medicine called Mefenamic Acid.
This medicine helps with tummy aches and other mild to medium pains.
This is good news for Marksans Pharma because it lets them sell more kinds of medicines in the UK.
The company recently shared its financial results, showing increased sales but a slight dip in profits.
They are hopeful about growing their business in the UK.
Marksans Pharma's UK arm, Relonchem Limited, received MHRA approval for Mefenamic Acid Film-Coated Tablets
The tablets are available in 250 mg and 500 mg strengths for mild to moderate pain relief
This approval expands Marksans Pharma's generic drug portfolio in the UK market
The company reported a net profit of ₹98.2 crore and revenue of ₹720 crore for the September quarter
Marksans Pharma's UK and Europe businesses contributed ₹245.3 crore in Q2 FY26, with a positive UK growth outlook
- Who
- Marksans Pharma's UK subsidiary, Relonchem Limited
- What
- Received authorisation from the MHRA to market Mefenamic Acid Film-Coated Tablets
- When
- Following the company's Q2 FY26 financial reporting
- Where
- United Kingdom
- Why
- To expand its offerings in the UK generics market and support future growth
- Company
- Marksans Pharma
- UK Subsidiary
- Relonchem Limited
- Regulatory Agency
- UK Medicines and Healthcare products Regulatory Agency (MHRA)
- Approved Product
- Mefenamic Acid Film-Coated Tablets (250 mg and 500 mg)
- Indication
- Short-term relief of mild to moderate pain, including menstrual pain
- Quarterly Financials (Q2 FY26)
- Net profit ₹98.2 crore (up 1.5%), Revenue ₹720 crore (up 12%), EBITDA ₹144.7 crore (down 1.7%)